<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03471806</url>
  </required_header>
  <id_info>
    <org_study_id>S60362-BN</org_study_id>
    <nct_id>NCT03471806</nct_id>
  </id_info>
  <brief_title>Dopamine Release to Food Reward in Bulimia Nervosa</brief_title>
  <official_title>Dopamine Release to Food Reward in Bulimia Nervosa: an [18F]-Fallypride PET/MR Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the role of dopamine responses to food reward in Bulimia Nervosa&#xD;
      patients, by performing simultaneous Positron Emission Tomography (PET) and Magnetic&#xD;
      Resonance (MR) scanning. The dopamine response will be measured before and after treatment,&#xD;
      and will be compared to healthy controls.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bulimia nervosa is a psychiatric eating disorder characterized by recurrent episodes of binge&#xD;
      eating, followed by inappropriate compensatory behaviour. It is associated with a high&#xD;
      disease burden and high rates of medical and psychiatric comorbidities. Only 50% of patients&#xD;
      achieve long-term remission, indicating the need for a better understanding of the&#xD;
      pathophysiology which can guide the development of new treatment options.&#xD;
&#xD;
      There are strong indications for an involvement of the brain's dopaminergic reward system in&#xD;
      Bulimia Nervosa, such as the presence of elevated craving for rewarding food and poorer&#xD;
      impulse control. However, there is no clear evidence on the exact involvement of the reward&#xD;
      system nor direct evidence of abnormal dopamine responses to food reward. Therefore, the&#xD;
      current study will assess dopamine release and related brain activity to food reward in&#xD;
      Bulimia Nervosa patients, by performing simultaneous Positron Emission Tomography (PET) and&#xD;
      Magnetic Resonance (MR) scanning. Specifically, the investigators will compare dopamine&#xD;
      release in Bulimia Nervosa patients to healthy controls, and assess the effect of successful&#xD;
      treatment on the food reward response. To this end, 20 Bulimia Nervosa patients will&#xD;
      participate in one PET-MR scan before the start of inpatient treatment and in a second PET-MR&#xD;
      scan at the end of inpatient treatment. Additionally, PET-MR scans will be obtained from a&#xD;
      group of 20 healthy control participants.&#xD;
&#xD;
      All scan session will measure dopamine release to a combination of anticipatory (viewing&#xD;
      high-calorie food images) and consummatory (drinking sips of chocolate milkshake) food reward&#xD;
      and will be conducted in a fasted state. The scan sessions will consist of four blocks with a&#xD;
      duration of 45 minutes each and 15 minute breaks in between. The first three blocks represent&#xD;
      the 'control condition' and the fourth block the 'food reward condition'. During both&#xD;
      sessions, blood samples will be collected at several time points to assess levels of&#xD;
      metabolic hormones and their relation to food-induced dopamine release.&#xD;
&#xD;
      This study aims to improve our understanding of the disease process underlying Bulimia&#xD;
      Nervosa and to enable the identification of new and specific treatment targets at multiple&#xD;
      levels of the gut-brain axis, including the dopamine system in the brain but also metabolic&#xD;
      hormones and the interactions between both. Additionally, the results may have the potential&#xD;
      to guide the optimisation of behavioural treatment approaches with a stronger focus on&#xD;
      aberrant reward system responses.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date type="Actual">February 16, 2018</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dopamine release to food reward in Bulimia Nervosa patients compared to healthy controls</measure>
    <time_frame>Continuously over 225 minutes after onset scanning; at baseline (before onset treatment of patients)</time_frame>
    <description>Comparison of dopamine release to food reward between Bulimia Nervosa patients and healthy controls. Dopamine release is defined as changes in [18F]-Fallypride binding potential in the food reward condition, with a kinetic linearized simplified reference region model (LSSRM) model.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in dopamine release to food reward in Bulimia Nervosa patients before and after treatment</measure>
    <time_frame>Continuously over 225 minutes after onset scanning; before and after inpatient treatment</time_frame>
    <description>Comparison of dopamine release to food reward before and after inpatient treatment for Bulimia Nervosa. Dopamine release is defined as changes in [18F]-Fallypride binding potential in the food reward condition, with a kinetic linearized simplified reference region model (LSSRM) model.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite measure of metabolic hormone levels</measure>
    <time_frame>5 minutes before onset scanning and 45, 105, 165, 180, 195, 210 and 225 minutes after onset scanning</time_frame>
    <description>Correlation between dopamine response to food reward and (changes in) metabolic hormone levels (ghrelin, motilin, glucagon-like peptide 1, peptide tyrosine tyrosine, leptin, and insulin)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Bulimia Nervosa</condition>
  <condition>Food Reward</condition>
  <arm_group>
    <arm_group_label>Bulimia Nervosa patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bulimia Nervosa patient group: Assessment of dopamine release to food reward at baseline (before treatment) and to food reward after treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy control group: Assessment of dopamine release to food reward at baseline, for comparison with Bulimia Nervosa patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Food reward at baseline</intervention_name>
    <description>Exposure to a combination of anticipatory (viewing high-calorie food images) and consummatory food reward (drinking sips of chocolate milkshake), at baseline.</description>
    <arm_group_label>Bulimia Nervosa patients</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Food reward after treatment</intervention_name>
    <description>Exposure to a combination of anticipatory (viewing high-calorie food images) and consummatory food reward (drinking sips of chocolate milkshake), at the end of inpatient treatment.</description>
    <arm_group_label>Bulimia Nervosa patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patients with Bulimia Nervosa:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with Bulimia Nervosa based on DSM-5 criteria;&#xD;
&#xD;
          -  Admission for inpatient treatment;&#xD;
&#xD;
          -  Female (on hormonal contraception);&#xD;
&#xD;
          -  Dutch-speaking;&#xD;
&#xD;
          -  Right-handed;&#xD;
&#xD;
          -  Body Mass Index (BMI) of 18.5 - 25 kg/mÂ².&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medical, neurological or other psychiatric disorders;&#xD;
&#xD;
          -  Use of psychotropic medication in past 6 months;&#xD;
&#xD;
          -  Use of cannabis or other drugs of abuse in past 12 months;&#xD;
&#xD;
          -  Lactose-intolerance or food allergies;&#xD;
&#xD;
          -  Vegetarian diet;&#xD;
&#xD;
          -  Smoking;&#xD;
&#xD;
          -  Consumption of more than 7 alcoholic units per week;&#xD;
&#xD;
          -  Exposure to a significant amount of ionizing radiation in past 12 months;&#xD;
&#xD;
          -  Claustrophobia;&#xD;
&#xD;
          -  Contra-indications for Magnetic Resonance Imaging;&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
        Healthy control participants:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy females (on hormonal contraception);&#xD;
&#xD;
          -  Dutch-speaking;&#xD;
&#xD;
          -  Right-handed;&#xD;
&#xD;
          -  Stable body weight with BMI of 18.5 - 25 kg/mÂ².&#xD;
&#xD;
        Additional Exclusion Criteria:&#xD;
&#xD;
          -  Any psychiatric disorders;&#xD;
&#xD;
          -  Emotional or restraint eating behaviour.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lukas Van Oudenhove, Prof. dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitaire Ziekenhuizen Leuven</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitaire ziekenhuizen Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>March 5, 2018</study_first_submitted>
  <study_first_submitted_qc>March 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2018</study_first_posted>
  <last_update_submitted>March 13, 2018</last_update_submitted>
  <last_update_submitted_qc>March 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitaire Ziekenhuizen Leuven</investigator_affiliation>
    <investigator_full_name>Lukas Van Oudenhove</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Bulimia Nervosa</keyword>
  <keyword>Eating disorder</keyword>
  <keyword>Dopamine</keyword>
  <keyword>Food</keyword>
  <keyword>Reward</keyword>
  <keyword>Positron Emission Tomography</keyword>
  <keyword>Magnetic Resonance</keyword>
  <keyword>Metabolic hormones</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bulimia</mesh_term>
    <mesh_term>Bulimia Nervosa</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

